Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

Biogen Idec building

Rocky start for Biogen’s Alzheimer’s drug Aduhelm

Controversial Alzheimer’s treatment Aduhelm is struggling to realise its potential, with only 100 patients receiving the therapy so far in the US

Changing human behaviour forever through software – only if humans allow

By David Williams

- PMLiVE

COVID-19 Pfizer/BioNTech booster approved by FDA and CDC

The plan to offer Americans a third, booster shot of the Pfizer/BioNTech COVID-19 vaccine has finally been waved through by the FDA and CDC

- PMLiVE

AstraZeneca invests in RNA tech platform

AstraZeneca will support research using VaxEquity’s RNA platform then pay at least $195m for each candidate that enters its pipeline

- PMLiVE

Market shaping demands behaviour change

By Nick Williams

Healthcare Access and Payment Reform in the US

Chris Saxman, Senior Healthcare Executive, Head of Product Strategy at UCM Digital Health, shares his thoughts on the US healthcare system, including its flaws and how to fix it; the...

Impetus Digital

Advancing Drug Discovery with Structured and Intelligent Data

Michael Wilson and Craig Knox, co-founders of DrugBank, discuss how their comprehensive drug database can be used together with AI and machine learning for drug discovery and repurposing, clinical research,...

Impetus Digital

- PMLiVE

Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role

Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.

Avalere Health

- PMLiVE

Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%

New data showing Gilead’s Veklury cuts the risk of hospitalisation for COVID-19 contradicts results of the World Health Organization’s Solidarity study

- PMLiVE

Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m

We Invest in People Gold logo

Cuttsy+Cuttsy awarded Gold accreditation by Investors in People

Healthcare communications agency, Cuttsy+Cuttsy, has been awarded ‘We invest in People, Gold’ from Investors in People.

Cuttsy + Cuttsy

- PMLiVE

Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in

By Dan Coffin

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links